Term | Definition |
ITP | An acquired thrombocytopenia caused by autoantibody-mediated destruction of platelets; the autoantibodies may also affect megakaryocytes and impair platelet production. ITP is a diagnosis of exclusion; the diagnosis cannot be made without investigations for other possible causes of thrombocytopenia. |
Bleeding severity | Several terms are used to describe bleeding severity. These are generally qualitative, and clinical judgment is needed to make these assessments.
|
Primary versus secondary ITP | Primary ITP is ITP not triggered by an apparent associated condition. Secondary ITP is ITP associated with a predisposing condition (examples listed below).* By convention, the associated condition is noted in parentheses, as in "Secondary ITP (SLE-associated)." |
Drug-induced ITP (DITP) | DITP is a drug reaction due to drug-dependent antibodies that cause platelet destruction. This syndrome should be distinguished from other, non-immune mechanisms of drug-induced thrombocytopenia such as bone marrow suppression.¶ |
New, persistent, and chronic ITP | The time elapsed since diagnosis determines whether ITP is referred to as newly diagnosed, persistent, or chronic. We use the following definitions:
|
First-line versus second-line therapy | First-line generally refers to glucocorticoids, IVIG, and anti-D immune globulin; these therapies are typically used for initial treatment of newly diagnosed patients or those with recurrent thrombocytopenia following a response. Second-line generally refers to treatment for ITP that does not respond to first-line therapy or that relapses after first-line therapy is tapered. Second-line treatments include splenectomy, rituximab, and TPO-RAs. |
Complete response versus partial response | A response to therapy is defined as at least doubling of the baseline platelet count and a platelet count >30,000/microL. A complete response is defined as a platelet count ≥100,000/microL; a partial response refers to a platelet count that doubles and is between 30,000 and 100,000/microL. |
Relapse | A fall in platelet count below 30,000/microL following a partial or complete response. |
Refractory disease | Definitions vary and include disease requiring treatment that persists or recurs after splenectomy or for which splenectomy is not an option. |